BioMarin Pharmaceutical Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$585.8M
Lead Investor(s):N/A

Estimated Revenue & Financials

  • BioMarin Pharmaceutical's total funding is $585.8M.

Employee Data

  • BioMarin Pharmaceutical has 3563 Employees.(?)
  • BioMarin Pharmaceutical currently has 1 job openings.

BioMarin Pharmaceutical Inc. develops enzyme therapies to treat debilitating, life-threatening genetic diseases and other indications. The Company has two enzyme replacement therapies in clinical trials and recently filed an application to enter a third enzyme into the clinic. Aldurazyme, a joint venture with Genzyme General, is an enzyme replacement therapy in a 45 patient, double-blind, placebo-controlled Phase III clinical trial to treat Mucopolysaccharidosis I (MPS I), a life-threatening genetic disease. On July 20, 2001, the Company completed the 24 week treatment stage of its Phase I clinical trial of rhASB, an enzyme replacement therapy for the treatment of MPS VI, a disease clinically similar to MPS I. Aldurazyme and rhASB have both received fast track status from the FDA, and they have also each been granted orphan designations in the U.S. and EU. The Company is also developing Vibriolysin Topical, an enzymatic gel for wound debridement (cleaning) in serious burn patients.